Hemodynamics News
-
Bodyport Announces Appointment of Jim Pursley to Board of Directors
Bodyport, a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions, announced today the appointment of Jim Pursley to the company’s board of directors. “I am excited to join the Bodyport Board of Directors as they reimagine care for patients living with complex chronic conditions. Bodyport’s focus on the patient has driven them to ...
-
Bodyport Receives FDA Clearance for the Bodyport Cardiac Scale
Bodyport, a digital therapeutics company on a mission to address complex chronic conditions, announced today that its noninvasive biomarker platform, the Bodyport Cardiac Scale™ received U.S. Food & Drug Administration (FDA) 510(k) clearance. This innovative solution enables people with fluid management conditions, such as heart failure and kidney disease, to noninvasively assess ...
-
Assessing Heart Function and Fluid Status with Cardiac Scales: Interview with John Lipman, CEO, and Corey Centen, Founder, Bodyport
Bodyport, a medtech company based in San Francisco, developed the Bodyport Cardiac Scale, a set of weighing scales that can non-invasively assess fluid status and heart function. The scales can detect these signals through the feet when a patient steps onto the device. The technology is intended to be convenient and requires only 20 seconds each morning, and should easily lend itself to ...
-
Bodyport Appoints John Lipman as Chief Executive Officer
Bodyport, a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions, today announced the appointment of medtech industry veteran, John Lipman, as Chief Executive Officer. Bodyport co-founder, Corey Centen, will continue as President and also serve as Chief Technology Officer (CTO) of the company. Lipman’s appointment comes as Bodyport prepares for ...
-
V-Wave’s Ventura interatrial shunt: one year follow-up from relieve-HF Roll-in arm shows improved left and right ventricular function in patients with advanced heart failure
V-Wave Ltd, manufacturer of the V-Wave Ventura investigational interatrial shunt device to help patients with advanced heart failure (HF), announced 12-month echocardiographic results from the open label Roll-in arm of the RELIEVE-HF pivotal clinical trial, comprising 97 NYHA Class III or ambulatory Class IV HF patients who were already on maximally tolerated guideline directed medical therapy. ...
By V-Wave Ltd.
-
CARMAT announces the publication of an article on the Aeson’s autoregulation system in the ASAIO Journal
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure,announces the publication of an articleon the Aeson’s autoregulation system in the October 2021 issue of the ASAIO Journal, a peer ...
By Carmat
-
CorWave Presented First Successful In Vivo 60-Day Study on Its Innovative LVAD Cardiac Support Device
CorWave announced that it successfully completed its first 60-day preclinical study to evaluate its Left Ventricular Assist Device (LVAD). The results were presented at the 46th Annual Conference of the European Society for Artificial Organs (ESAO) in Hannover. Trevor Snyder, PhD, Senior Director, Translational and Clinical Research at CorWave, delivered an oral presentation, “CorWave ...
By CorWave
-
Ultrasound Technology Answers COVID-Era Medical Training Challenges
The disruptive impact of the Covid-19 pandemic on medical services has been a central concern across our industry. The global health strategy, backed by guidance from the National Institutes of Health and World Health Organization, has so far focused on flattening the epidemiological curve. By doing so, we’ll prevent healthcare services, resources, and medical staff from being overwhelmed. ...
-
CorWave Reports Two Critical Technical Milestones Required to Proceed to the Clinical Phase at the American Society for Artificial Internal Organs Annual Meeting
CorWave announced today that the latest results of its preclinical Left Ventricular Assist Device (LVAD) development program are presented at the 2020 Virtual OnDemand Conference of the American Society for Artificial Organs (ASAIO), in the Top Abstracts session, available on the ASAIO website1. The presentation, entitled “In Silico, In Vitro and In Vivo Evaluation of the CorWave Membrane ...
By CorWave
-
AdjuCor announces first successful in vivo 60-day pre-clinical survival study using its cutting-edge, non-blood-contacting, biventricular cardiac support device.
MUNICH, Germany – October 2nd, 2019: After completing a 60-day pre-clinical study, Professor Stephen Wildhirt, MD, PhD, CEO at AdjuCor, is excited to report on its success. Apart from other achievements, the study confirmed the chronic physiologic acceptance of their non-blood-contacting biventricular cardiac support device by the body. AdjuCor has previously completed a successful 30-day ...
By AdjuCor GmbH
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you